Cargando…

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade

RET (REarranged during Transfection) is a receptor tyrosine kinase, which plays pivotal roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis. Activation of RET is a mechanism of oncogenesis in medullary thyroid carcinomas where both germline and sporadic activa...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, Amanda J., Hopkins, Gemma V., Hitchin, Samantha, Begum, Habiba, Jones, Stuart, Jordan, Allan, Holt, Sarah, March, H. Nikki, Newton, Rebecca, Small, Helen, Stowell, Alex, Waddell, Ian D., Waszkowycz, Bohdan, Ogilvie, Donald J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937820/
https://www.ncbi.nlm.nih.gov/pubmed/27429741
http://dx.doi.org/10.12688/f1000research.8724.2
_version_ 1782441775165603840
author Watson, Amanda J.
Hopkins, Gemma V.
Hitchin, Samantha
Begum, Habiba
Jones, Stuart
Jordan, Allan
Holt, Sarah
March, H. Nikki
Newton, Rebecca
Small, Helen
Stowell, Alex
Waddell, Ian D.
Waszkowycz, Bohdan
Ogilvie, Donald J.
author_facet Watson, Amanda J.
Hopkins, Gemma V.
Hitchin, Samantha
Begum, Habiba
Jones, Stuart
Jordan, Allan
Holt, Sarah
March, H. Nikki
Newton, Rebecca
Small, Helen
Stowell, Alex
Waddell, Ian D.
Waszkowycz, Bohdan
Ogilvie, Donald J.
author_sort Watson, Amanda J.
collection PubMed
description RET (REarranged during Transfection) is a receptor tyrosine kinase, which plays pivotal roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis. Activation of RET is a mechanism of oncogenesis in medullary thyroid carcinomas where both germline and sporadic activating somatic mutations are prevalent. At present, there are no known specific RET inhibitors in clinical development, although many potent inhibitors of RET have been opportunistically identified through selectivity profiling of compounds initially designed to target other tyrosine kinases. Vandetanib and cabozantinib, both multi-kinase inhibitors with RET activity, are approved for use in medullary thyroid carcinoma, but additional pharmacological activities, most notably inhibition of vascular endothelial growth factor - VEGFR2 (KDR), lead to dose-limiting toxicity. The recent identification of RET fusions present in ~1% of lung adenocarcinoma patients has renewed interest in the identification and development of more selective RET inhibitors lacking the toxicities associated with the current treatments. In an earlier publication [Newton et al, 2016; 1] we reported the discovery of a series of 2-substituted phenol quinazolines as potent and selective RET kinase inhibitors. Here we describe the development of the robust screening cascade which allowed the identification and advancement of this chemical series.  Furthermore we have profiled a panel of RET-active clinical compounds both to validate the cascade and to confirm that none display a RET-selective target profile.
format Online
Article
Text
id pubmed-4937820
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-49378202016-07-15 Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade Watson, Amanda J. Hopkins, Gemma V. Hitchin, Samantha Begum, Habiba Jones, Stuart Jordan, Allan Holt, Sarah March, H. Nikki Newton, Rebecca Small, Helen Stowell, Alex Waddell, Ian D. Waszkowycz, Bohdan Ogilvie, Donald J. F1000Res Research Article RET (REarranged during Transfection) is a receptor tyrosine kinase, which plays pivotal roles in regulating cell survival, differentiation, proliferation, migration and chemotaxis. Activation of RET is a mechanism of oncogenesis in medullary thyroid carcinomas where both germline and sporadic activating somatic mutations are prevalent. At present, there are no known specific RET inhibitors in clinical development, although many potent inhibitors of RET have been opportunistically identified through selectivity profiling of compounds initially designed to target other tyrosine kinases. Vandetanib and cabozantinib, both multi-kinase inhibitors with RET activity, are approved for use in medullary thyroid carcinoma, but additional pharmacological activities, most notably inhibition of vascular endothelial growth factor - VEGFR2 (KDR), lead to dose-limiting toxicity. The recent identification of RET fusions present in ~1% of lung adenocarcinoma patients has renewed interest in the identification and development of more selective RET inhibitors lacking the toxicities associated with the current treatments. In an earlier publication [Newton et al, 2016; 1] we reported the discovery of a series of 2-substituted phenol quinazolines as potent and selective RET kinase inhibitors. Here we describe the development of the robust screening cascade which allowed the identification and advancement of this chemical series.  Furthermore we have profiled a panel of RET-active clinical compounds both to validate the cascade and to confirm that none display a RET-selective target profile. F1000Research 2016-08-23 /pmc/articles/PMC4937820/ /pubmed/27429741 http://dx.doi.org/10.12688/f1000research.8724.2 Text en Copyright: © 2016 Watson AJ et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Watson, Amanda J.
Hopkins, Gemma V.
Hitchin, Samantha
Begum, Habiba
Jones, Stuart
Jordan, Allan
Holt, Sarah
March, H. Nikki
Newton, Rebecca
Small, Helen
Stowell, Alex
Waddell, Ian D.
Waszkowycz, Bohdan
Ogilvie, Donald J.
Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
title Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
title_full Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
title_fullStr Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
title_full_unstemmed Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
title_short Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascade
title_sort identification of selective inhibitors of ret and comparison with current clinical candidates through development and validation of a robust screening cascade
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937820/
https://www.ncbi.nlm.nih.gov/pubmed/27429741
http://dx.doi.org/10.12688/f1000research.8724.2
work_keys_str_mv AT watsonamandaj identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT hopkinsgemmav identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT hitchinsamantha identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT begumhabiba identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT jonesstuart identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT jordanallan identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT holtsarah identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT marchhnikki identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT newtonrebecca identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT smallhelen identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT stowellalex identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT waddelliand identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT waszkowyczbohdan identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade
AT ogilviedonaldj identificationofselectiveinhibitorsofretandcomparisonwithcurrentclinicalcandidatesthroughdevelopmentandvalidationofarobustscreeningcascade